Document Server@UHasselt >
School for Information Technology >
Master theses >
Please use this identifier to cite or link to this item:
|Title: ||Validation of PFS as surrogate for overall survival for GBM|
|Authors: ||Nangosyah, Julius|
|Advisors: ||BURZYKOWSKI, Tomasz|
|Issue Date: ||2013|
Background: Surrogate end points have great potential for use in clinical oncology, but their statistical validation presents major challenges12. A putative surrogate endpoint must be validated at both individual-level and trial-level before it can be used to replace the clinical endpoint in a future clinical trial34. Validated and approved surrogate endpoints are useful in development of new drugs. They save time and money since it takes a shorter time to give results. They also require fewer patients in the clinical trial.
Objective: To evaluate progression free survival as a surrogate for overall survival for the patients who have been newly diagnosed with Glioblastoma.
Methodology: Individual patients were available from two trials comparing radiotherapy alone (379 patients) with radiotherapy plus chemotherapy (389 patients).Correlation coefficients were estimated between the endpoints of PFS and OS through Cox proportional model and copula models. These methods were a|
|Notes: ||Master of Statistics-Biostatistics|
|Type: ||Theses and Dissertations|
|Appears in Collections: ||Master theses|
Files in This Item:
|N/A||589.8 kB||Adobe PDF|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.